SCHEMBL2019654

SCHEMBL2019654

NCc1cccc(N)c1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 1/20 0.43
PNMT P11086 3/20 0.43
GABRA1 P14867 2/20 0.41
GABRB2 P47870 2/20 0.41
TSHR P16473 2/20 0.39
ALOX15 P16050 2/20 0.39
HMGB1 P09429 1/20 0.37
ABAT P80404 1/20 0.37
TAAR1 Q96RJ0 1/20 0.37
DPP4 P27487 1/20 0.37
ENPP2 Q13822 1/20 0.37
CYP3A4 P08684 2/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
HSD17B10 Q99714 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
AOC1 P19801 1/20 0.35
AOC3 Q16853 1/20 0.35
CASP1 P29466 1/20 0.35
CASP7 P55210 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20182944 0.85 GABRA1 (0.55) MMP2PNMTGABRA1GABRB2ALOX15
SCHEMBL564241 0.83 MMP2 (0.45) MMP2GABRA1GABRB2TSHRALOX15
SCHEMBL10762848 0.82 HMGB1 (0.56) MMP2ALOX15HMGB1TAAR1HSD17B10
SCHEMBL14967117 0.81 MMP2 (0.43) MMP2GABRA1GABRB2TSHRALOX15
SCHEMBL4105394 0.79 GABRA1 (0.70) MMP2GABRA1GABRB2TSHRALOX15
SCHEMBL366656 0.78 ADAMTS4 (0.52) MMP2PNMTGABRA1GABRB2ALOX15
Bromide SCHEMBL4967570 0.77 GABRA1 (0.67) MMP2GABRA1GABRB2TSHRCYP3A4
SCHEMBL14895143 0.77 MMP2 (0.41) MMP2GABRA1GABRB2TSHRALOX15
SCHEMBL24349403 0.76 GABRA1 (0.46) PNMTGABRA1GABRB2HMGB1ABAT
Hydrochloric Acid SCHEMBL1998632 0.76 ADAMTS4 (0.50) MMP2PNMTGABRA1GABRB2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8519168-B2 Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds MERCK SHARP & DOHME CORP. (US) 2013-08-27 US disclosed
US-20110160469-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS MERCK SHARP & DOHME LLC 2011-06-30 US disclosed
EP-2178826-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS SCHERING CORPORATION (US) 2010-04-28 EP disclosed
WO-2009005801-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS SCHERING CORPORATION (US) 2009-01-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110160469-A1 PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 1,2-SUBSTITUTED 3,4-DIOXO-1-CYCLOBUTENE COMPOUNDS CCL2, CCR1, CXCR1 MMP2 2261/4885PNMT 4302/4885GABRA1 3995/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.